The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded a single award indefinite delivery contract to Cytopath Biopsy Lab Inc., doing business as Cblpath, with a potential value of $500,000. Cblpath will provide thyroid cancer diagnostic testing services to support VA-VHA programs through August 2028. A $72,000 firm fixed price delivery order was also awarded for one year of clinical molecular ThyroSeq testing services in the San Francisco area from August 2023 through August 2024. The ThyroSeq Next-Generation Sequencing test analyzes DNA for over 500 genetic alterations associated with thyroid cancer, aiding in diagnosis and treatment decisions. This supports the clinical testing needs of VA medical centers in the region. The original solicitation sought these thyroid cancer diagnostic testing services to determine nodule thyroid malignancy in surgical decisions, with responses due by May 29, 2023. No set-asides were used under the contract or delivery order.
The indefinite delivery contract and associated delivery order aim to procure specialized thyroid cancer diagnostic testing services from Cblpath to assist the VA-VHA with surgical treatment decisions for veterans in the San Francisco area. The ThyroSeq Next-Generation Sequencing test will analyze genetic information to help accurately diagnose thyroid conditions and guide care. This supports the overall health mission of the VA by ensuring veterans receive informed medical treatment.
Generated 1/5/24, 6:00 PM